Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous ...

Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation ...

The CB 1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no ...

The company plans to engage with the FDA during the fourth quarter of 2024 with the results of this pharmacokinetics study and obtain feedback that will assist with the AD04 Phase 3 study program.

Eupraxia Pharmaceuticals (EPRX)unveiled new pharmacokinetic, or PK data from its Phase 2a Eosinophilic Esophagitis, or EoE, program.

Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

PK data analysis in dose-escalation phase indicated exposures of QRL-201 met or exceeded the targeted therapeutic range promptin ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

Technologies announced the completion of enrollment in its Phase 2 Study of PL8177, a potent melanocortin-1 receptor agonist, in ...